129448-97-1|RB 6145|1H-Imidazole-1-ethanol, alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, monohydrobromide|-范德生物科技公司

RB 6145

NMR下载 COA and HPLC MSDS下载
names：
1H-Imidazole-1-ethanol, alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, monohydrobromide
CAS号：
129448-97-1
MDL Number：
MF(分子式)： C8H14Br2N4O3 MW(分子量)： 374.03
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	1H-Imidazole-1-ethanol, alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, monohydrobromide
英文别名	RB 6145; RB-6145; RB6145
CAS号	129448-97-1
Inchi	InChI=1S/C8H13BrN4O3.BrH/c9-1-2-10-5-7(14)6-12-4-3-11-8(12)13(15)16;/h3-4,7,10,14H,1-2,5-6H2;1H
InchiKey	XPBJPGMCFKYBBV-UHFFFAOYSA-N
分子式 Formula	C8H14Br2N4O3
分子量 Molecular Weight	374.03
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	RB 6145(CAS:129448-97-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	RB 6145 is an anticancer drug.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Winters T, Sercel A, Suto C, Elliott W, Leopold W, Leopold J, Showalter H. Design and synthesis of 2-nitroimidazoles with variable alkylating and acylating functionality. Chem Pharm Bull (Tokyo). 2014;62(3):301-3. PubMed PMID: 24583786.

[2]Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br J Cancer. 2010 Jul 13;103(2):201-8. doi: 10.1038/sj.bjc.6605753. Epub 2010 Jun 29. PubMed PMID: 20588272; PubMed Central PMCID: PMC2906743.

[3] Miller TJ, Schneider RJ, Miller JA, Martin BP, Al-Ubaidi MR, Agarwal N, Dethloff LA, Philbert MA. Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. Neurotoxicology. 2006 Jan;27(1):44-59. Epub 2005 Aug 24. PubMed PMID: 16125243.

[4] Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res. 2005 Jun 1;11(11):4212-6. PubMed PMID: 15930359.

[5] Miller TJ, Phelka AD, Tjalkens RB, Dethloff LA, Philbert MA. CI-1010 induced opening of the mitochondrial permeability transition pore precedes oxidative stress and apoptosis in SY5Y neuroblastoma cells. Brain Res. 2003 Feb 14;963(1-2):43-56. PubMed PMID: 12560110.

6: Olive PL, Banáth JP, Durand RE. The range of oxygenation in SiHa tumor xenografts. Radiat Res. 2002 Aug;158(2):159-66. PubMed PMID: 12105985.7: Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 2002 Jul;9(14):946-54. PubMed PMID: 12085243.8: Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol. 2000 Feb 15;163(1):50-9. PubMed PMID: 10662604.9: Breider MA, Ulloa HM, Pegg DG, Gough AW. Nitro-imidazole radiosensitizer-induced toxicity in cynomolgus monkeys. Toxicol Pathol. 1998 Sep-Oct;26(5):651-6. PubMed PMID: 9789952.10: Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 1998 Aug;78(4):439-45. PubMed PMID: 9716024; PubMed Central PMCID: PMC2063102.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开